Gelesis100 Reduces Insulin-Resistance in GLOW Obesity Trial
Executive Summary
Data from the pivotal GLOW trial presented at the Endocrine Society's annual meeting show that Gelesis' Gelesis100 non-systemic, superabsorbent hydrogel significantly reduces insulin-resistance compared to placebo in overweight and obese patients.
You may also be interested in...
Gelesis Presents Data Showing GS200, The Device That Looks Like A Drug, Treats Obesity
Results of the LIGHT UP study, which included prediabetic and diabetic subjects, could support FDA approval of GS200.
Gelesis's Plenity Obesity Product Earns De Novo For Wide BMI Range
PureTech's affiliate Gelesis has received US FDA de novo clearance for its Plenity capsule to treat overweight-obese adults, and plans to launch it commercially in the second half.
Gelesis Absorbs Clinical Affairs and Commercial Expertise With New Appointments
Gelesis reels in former Walgreens and Boehringer Ingelheim execs as it prepares to take its anti-obesity capsule-based treatment towards regulatory approvals.